Blog

Home  /  Covid-19   /  PTRCR18 – Dexamethasone for the treatment of hospitalised patients with COVID-19 – Final Rapid Collaborative Review now available.

PTRCR18 – Dexamethasone for the treatment of hospitalised patients with COVID-19 – Final Rapid Collaborative Review now available.

This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA. This report describes dexamethasone for the treatment of COVID-19 patients.

In September, 2020, the European Commission endorsed the use of dexamethasone for the treatment of COVID-19 patients on oxygen or mechanical venilation. This Rapid Collaborative Review aims to define, according to the national requirements of the EUnetHTA partners, the PICO, an overview of available evidence and Evidence gaps of dexamethasone in the target patient populations with relevant comparators.

For any questions regarding the Rapid Collaborative Review, please contact eunethta@zinl.nl.

Please find the review here:

PTRCR18 – Final Rapid Collaborative Review